A detailed history of Aqr Capital Management LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 29,709 shares of MYGN stock, worth $408,201. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,709
Previous 20,910 42.08%
Holding current value
$408,201
Previous $511,000 59.1%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.97 - $28.6 $210,912 - $251,651
8,799 Added 42.08%
29,709 $813,000
Q2 2024

Aug 14, 2024

BUY
$17.98 - $25.47 $56,025 - $79,364
3,116 Added 17.51%
20,910 $511,000
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $190,042 - $254,866
-10,804 Reduced 37.78%
17,794 $379,000
Q4 2023

Feb 14, 2024

SELL
$13.91 - $21.32 $421,848 - $646,571
-30,327 Reduced 51.47%
28,598 $547,000
Q3 2023

Nov 14, 2023

BUY
$15.99 - $23.22 $65,718 - $95,434
4,110 Added 7.5%
58,925 $945,000
Q2 2023

Aug 14, 2023

BUY
$17.56 - $23.76 $279,432 - $378,092
15,913 Added 40.91%
54,815 $1.27 Million
Q1 2023

May 15, 2023

SELL
$15.26 - $23.75 $400,727 - $623,675
-26,260 Reduced 40.3%
38,902 $903,000
Q4 2022

Feb 14, 2023

SELL
$14.51 - $20.99 $66,644 - $96,407
-4,593 Reduced 6.58%
65,162 $945,000
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $436,074 - $667,642
23,947 Added 52.28%
69,755 $1.33 Million
Q2 2022

Aug 15, 2022

SELL
$16.45 - $25.88 $543,524 - $855,101
-33,041 Reduced 41.9%
45,808 $832,000
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $345,218 - $426,536
-15,228 Reduced 16.19%
78,849 $1.99 Million
Q4 2021

Feb 14, 2022

BUY
$24.13 - $32.63 $1.01 Million - $1.37 Million
42,041 Added 80.79%
94,077 $2.6 Million
Q3 2021

Nov 15, 2021

BUY
$29.97 - $36.66 $321,068 - $392,738
10,713 Added 25.93%
52,036 $1.68 Million
Q2 2021

Aug 16, 2021

BUY
$25.39 - $32.61 $564,724 - $725,311
22,242 Added 116.57%
41,323 $1.26 Million
Q1 2021

May 17, 2021

SELL
$19.92 - $31.6 $271,489 - $430,676
-13,629 Reduced 41.67%
19,081 $581,000
Q4 2020

Feb 16, 2021

SELL
$12.16 - $19.77 $781,048 - $1.27 Million
-64,231 Reduced 66.26%
32,710 $647,000
Q3 2020

Nov 16, 2020

SELL
$11.25 - $14.75 $756,281 - $991,568
-67,225 Reduced 40.95%
96,941 $1.26 Million
Q2 2020

Aug 17, 2020

BUY
$10.69 - $16.49 $262,118 - $404,334
24,520 Added 17.56%
164,166 $1.86 Million
Q1 2020

May 15, 2020

SELL
$9.78 - $29.53 $842,380 - $2.54 Million
-86,133 Reduced 38.15%
139,646 $2 Million
Q4 2019

Feb 14, 2020

SELL
$20.93 - $35.1 $1.55 Million - $2.59 Million
-73,839 Reduced 24.64%
225,779 $6.15 Million
Q3 2019

Nov 14, 2019

BUY
$22.08 - $47.08 $1.73 Million - $3.69 Million
78,363 Added 35.42%
299,618 $8.58 Million
Q2 2019

Aug 14, 2019

SELL
$22.67 - $35.0 $1.03 Million - $1.59 Million
-45,355 Reduced 17.01%
221,255 $6.15 Million
Q1 2019

May 14, 2019

SELL
$26.93 - $34.7 $1.54 Million - $1.98 Million
-57,108 Reduced 17.64%
266,610 $8.85 Million
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $913,103 - $1.53 Million
-33,533 Reduced 9.39%
323,718 $9.41 Million
Q3 2018

Nov 15, 2018

BUY
$37.57 - $50.34 $668,483 - $895,699
17,793 Added 5.24%
357,251 $16.4 Million
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $828,975 - $1.2 Million
-29,873 Reduced 8.09%
339,458 $12.7 Million
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $260,796 - $370,976
-9,046 Reduced 2.39%
369,331 $10.9 Million
Q4 2017

Feb 14, 2018

BUY
$28.45 - $37.14 $3.53 Million - $4.61 Million
124,087 Added 48.8%
378,377 $13 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $6.11 Million - $9.21 Million
254,290
254,290 $9.2 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.